- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 239/28 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
Patent holdings for IPC class C07D 239/28
Total number of patents in this class: 339
10-year publication summary
|
36
|
31
|
26
|
20
|
26
|
14
|
19
|
20
|
17
|
5
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Corteva Agriscience LLC | 2669 |
12 |
| Syngenta Participations AG | 1903 |
11 |
| CHDI Foundation, Inc. | 108 |
11 |
| Novartis AG | 10849 |
8 |
| Theravance Biopharma R&D IP, LLC | 458 |
8 |
| BASF SE | 20933 |
7 |
| Boehringer Ingelheim International GmbH | 4650 |
6 |
| Incyte Corporation | 1024 |
6 |
| Purdue Pharma L.P. | 499 |
6 |
| Bristol-myers Squibb Company | 4898 |
5 |
| Bayer AG | 3330 |
5 |
| Bayer Cropscience AG | 2035 |
5 |
| Merck Sharp & Dohme LLC | 3748 |
5 |
| Hoffmann-La Roche Inc. | 3418 |
4 |
| The Regents of the University of California | 19918 |
4 |
| Janssen Pharmaceutica N.V. | 3392 |
4 |
| Takeda Pharmaceutical Company Limited | 2713 |
4 |
| F. Hoffmann-La Roche AG | 7925 |
3 |
| Genentech, Inc. | 3976 |
3 |
| Merck Patent GmbH | 5831 |
3 |
| Other owners | 219 |